Tag: otoferlin-deficiency

All

Sensorion Names SENS-601 Lead Gene Therapy Program, Files Clinical Trial Applications for GJB2-Related Hearing Loss

Sensorion is focusing on SENS-601 targeting GJB2 mutations, while discontinuing development of its OTOF-targeting program, SENS-501.

Gene Therapy for Inherited Deafness Provides Lasting Hearing Restoration
FDA Grants Accelerated Approval to Otarmeni Gene Therapy for OTOF-Related Hearing Loss
FDA Expediting Review of Regeneron Drug to Treat Genetic Hearing Loss
New DB-OTO Results Show Sustained Improvements for Children with Profound Genetic Hearing Loss
Sensorion Completes Second Cohort Enrollment in OTOF Gene Therapy Clinical Trial
Sensorion Announces Positive Data from Audiogene SENS-501 Clinical Trial

All

Study: OTOF Gene Therapy Restored Hearing in Deaf Patients

In a new study, gene therapy targeting the OTOF gene significantly restored hearing in children and adults with congenital deafness, with rapid improvement and no serious side effects.

Regeneron’s Gene Therapy DB-OTO Trial Shows Promising Hearing Improvement
France Approves Gene Therapy Clinical Trial to Treat Hearing Loss in Children
Akouos’ AK-OTOF Receives Orphan Drug Designation
Akouos Receives FDA Designations for AK-OTOF
Sensorion Announces Gene Therapy Collaboration
Decibel Therapeutics and Invitae Launch Amplify Testing

All

Decibel Therapeutics Receives $82.2 Million Series D Financing for Advancement of Hearing Therapies

Proceeds will be used in part to support clinical and preclinical studies needed to advance Decibel’s therapeutic pipeline.

Akouos Announces Gene Therapy to Treat Genetic Hearing Loss
Sensorion Partners with Institut Pasteur on Research Framework Targeting Hearing Loss
Sensorion and Pasteur Institute to Collaborate on Gene Therapy Products

Tag: otoferlin-deficiency

All

Sensorion Names SENS-601 Lead Gene Therapy Program, Files Clinical Trial Applications for GJB2-Related Hearing Loss

Gene Therapy for Inherited Deafness Provides Lasting Hearing Restoration

FDA Grants Accelerated Approval to Otarmeni Gene Therapy for OTOF-Related Hearing Loss

FDA Expediting Review of Regeneron Drug to Treat Genetic Hearing Loss

New DB-OTO Results Show Sustained Improvements for Children with Profound Genetic Hearing Loss

Sensorion Completes Second Cohort Enrollment in OTOF Gene Therapy Clinical Trial

Sensorion Announces Positive Data from Audiogene SENS-501 Clinical Trial

All

Study: OTOF Gene Therapy Restored Hearing in Deaf Patients

Regeneron’s Gene Therapy DB-OTO Trial Shows Promising Hearing Improvement

France Approves Gene Therapy Clinical Trial to Treat Hearing Loss in Children

Akouos’ AK-OTOF Receives Orphan Drug Designation

Akouos Receives FDA Designations for AK-OTOF

Sensorion Announces Gene Therapy Collaboration

Decibel Therapeutics and Invitae Launch Amplify Testing

All

Decibel Therapeutics Receives $82.2 Million Series D Financing for Advancement of Hearing Therapies

Akouos Announces Gene Therapy to Treat Genetic Hearing Loss

Sensorion Partners with Institut Pasteur on Research Framework Targeting Hearing Loss

Sensorion and Pasteur Institute to Collaborate on Gene Therapy Products

Sorry, No Posts Found

The Hearing Review

Our Parent Company

Key Resources

Helpful Links